Floatz logo

Selpercatinib

Congenital Fibrosarcoma

Eli Lilly and CompanySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Congenital Fibrosarcoma cohort.

Asset / SponsorPhaseRating
Larotrectinib
Bayer
UnknownD
bay2757556
Bayer
UnknownD

Same molecule, other indications

Selpercatinib is also rated in:

medullary thyroid gland carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →
soft tissue sarcomaActive
B
Indicative · Phase 2
60 / 100
View asset →
non-small cell lung carcinomaActive
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →